propranolol ER / Generic mfg. - LARVOL DELTA

Propranolol Mitigates Cardiovascular Effects of CPAP Withdrawal (ATS 2025) - " We performed a double-blind randomized crossover trial of propranolol (Inderal LA 80 mg, PRO) vs. placebo (PLA) in patients with OSA during 3-night CPAP withdrawal. 21 participants (51±11 years old, 62% male, BMI 33.8 ± 6.8 kg/m2) completed the study. As expected, CPAP withdrawal led to resumption of severe OSA (AHI 43 events/hr). PRO decreased mean overnight HR by 3.9 beats /min (p<0.001)."

Cardiovascular • CNS Disorders • Congestive Heart Failure • Heart Failure • Hypotension • Obstructive Sleep Apnea • Respiratory Diseases • Sleep Disorder

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Cardiovascular

Thyroid Storm at Sea: A Case of Algae Induced Thyrotoxicosis (AACE 2024) - "She received intravenous Metoprolol for control of tachycardia, propylthiouracil (PTU), decadron, potassium iodine, and insulin infusion for DKA. PTU was changed to Methimazole and cholestyramine on day 2 due to worsening transaminitis. On day 5, she was transitioned to long acting Propranolol, Methimazole, and a tapered steroid course...Beta blockers with or without antithyroid drugs are the mainstay of treatment for iodine induced thyrotoxicosis. Healthcare providers should warn patients of the potential dangers of unregulated supplements, particularly about using iodine containing seaweed products which can be toxic to the thyroid even in small quantities."

Clinical • Cardiovascular • Critical care • Diabetes • Endocrine Disorders • Metabolic Disorders • Ophthalmology • Type 1 Diabetes Mellitus

A rare pesentation of Alirocumab-mediated acute interstitial nephritis (NKF-SCM 2024) - "His current medications included ramipril 5mg, rosuvastatin 40mg, propranolol ER 60mg, aspirin 81mg, and alirocumab.He had begun once a month alirocumab as part of a lipid lowering therapy regimen 4 months ago, and he had taken 3 doses in total...Renal biopsy revealed changes consistent with acute interstitial nephritis with negative staining for IgG4 presence.He received 2 sessions of hemodialysis.Aloricumab held.He was started on prednisone 60mg x 2 weeks followed by taper.All other causes of AIN were thoroughly excluded.Creatinine slowly trended down to 1.8... Alirocumab is an increasingly popular second-line medication prescribed for the treatment of hypercholesterolemia. While few side effects are well known, the potential renal side effects of the medication have not been well documented except ATN in form of a case report. To our knowledge, our case represents the first incidence of acute interstitial nephritis associated with alirocumab injection as shown by the..."

Cardiovascular • Coronary Artery Disease • Dyslipidemia • Fatigue • Hypertension • Metabolic Disorders • Nephrology • Vasculitis

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Dec 2023 ➔ Dec 2024 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Trial completion date • Trial primary completion date • Cardiovascular

"Amen. And propranolol ER in particular." (@jarenblake)

Teprotumumab Induced Type 1 Diabetes Mellitus (AACE 2023) - "Her levothyroxine was stopped by PCP and she was started on methimazole 10 mg tid and propranolol ER 60 mg daily...She was started on metformin XR 500 mg bid given her diagnosis of prediabetes and plan for Teprotumumab therapy. She achieved smoking cessation with varenicline...Subsequently methimazole was decreased to 2.5 mg daily and Metformin increased to 1g bid and addition of glimepiride 2mg daily...Further evaluation for this patient is still pending with initiation of insulin therapy. We hope that this case can help guide research, safety protocols, and awareness in the management of thyroid eye disease."

Diabetes • Endocrine Disorders • Metabolic Disorders • Nicotine Addiction • Ophthalmology • Thyroid Eye Disease • Tobacco Cessation • Type 1 Diabetes Mellitus

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Vanderbilt University Medical Center | Trial completion date: Dec 2022 ➔ Dec 2023 | Trial primary completion date: Dec 2022 ➔ Dec 2023

Trial completion date • Trial primary completion date • Cardiovascular

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1 | N=80 | Completed | Sponsor: Christiana Care Health Services | Recruiting ➔ Completed

Trial completion • Obstetrics

Long-term esthetic outcome of treatment with propranolol or atenolol for infantile hemangioma (ESPD 2022) - No abstract available.

Neurocognitive functioning, physical health, and mental health of school-aged children treated with propranolol or atenolol for infantile hemangioma (ESPD 2022) - "In children aged 6 months to <6 years with moderate-to-severe AD, dupilumab q4w+low-potency TCS rapidly and signifi-cantly improved AD signs and symptoms. Dupilumab was well toler-ated and demonstrated an acceptable safety profile."

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Christiana Care Health Services | N=200 ➔ 80

Enrollment change

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1 | N=200 | Recruiting | Sponsor: Christiana Care Health Services | Trial primary completion date: Jan 2022 ➔ Jun 2022

Trial primary completion date

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Vanderbilt University Medical Center; Trial completion date: Dec 2021 ➔ Dec 2022; Trial primary completion date: Dec 2021 ➔ Dec 2022

Trial completion date • Trial primary completion date • Cardiovascular

BISP: Biopsychosocial Influence on Shoulder Pain (clinicaltrials.gov) - P2; N=264; Completed; Sponsor: Duke University; Recruiting ➔ Completed; N=448 ➔ 264

Enrollment change • Preclinical • Trial completion • Musculoskeletal Pain • Pain • IL1B • IL6 • TNFA

Study of Propranolol in Newly Diagnosed Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy (clinicaltrials.gov) - P2; N=10; Completed; Sponsor: Columbia University; Active, not recruiting ➔ Completed

Clinical • Trial completion • Breast Cancer • HER2 Breast Cancer • HER2 Positive Breast Cancer • Hormone Receptor Breast Cancer • Oncology • Solid Tumor • HER-2

PRO-Labor: Propranolol for Protracted Labor (clinicaltrials.gov) - P1; N=200; Recruiting; Sponsor: Christiana Care Health Services; Not yet recruiting ➔ Recruiting

Enrollment open

Perioperative Propranolol in Patients With Post Traumatic Stress Disorder (PTSD) (clinicaltrials.gov) - P=N/A; N=59; Terminated; Sponsor: University of California, San Francisco; N=110 ➔ 59

Enrollment change • CNS Disorders • Mood Disorders • Post-traumatic Stress Disorder

Study of Propranolol to Decrease Gene Expression of Stress-Mediated Beta-Adrenergic Pathways in HCT Recipients (clinicaltrials.gov) - P2; N=25; Completed; Sponsor: Medical College of Wisconsin; Active, not recruiting ➔ Completed

Clinical • Trial completion • Bone Marrow Transplantation • Hematological Malignancies • Mood Disorders • Multiple Myeloma • Neutropenia • Oncology • Transplantation

BISP: Biopsychosocial Influence on Shoulder Pain (clinicaltrials.gov) - P2; N=448; Recruiting; Sponsor: Duke University; Trial completion date: Apr 2021 ➔ Oct 2021; Trial primary completion date: Apr 2021 ➔ Oct 2021

Preclinical • Trial completion date • Trial primary completion date • Musculoskeletal Pain • Pain • IL1B • IL6

PRO-Labor: Propranolol Versus Placebo at Time of Labor Induction for Protracted Labor (clinicaltrials.gov) - P1; N=200; Not yet recruiting; Sponsor: Christiana Care Health Services

Clinical • New P1 trial

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Vanderbilt University Medical Center; Trial completion date: Dec 2020 ➔ Dec 2021; Trial primary completion date: Dec 2020 ➔ Dec 2021

Trial completion date • Trial primary completion date • Cardiovascular

Functional Imaging of Tremor Circuits and Mechanisms of Treatment Response (clinicaltrials.gov) - P4; N=56; Completed; Sponsor: University of California, San Diego; Active, not recruiting ➔ Completed; Phase classification: PN/A ➔ P4

Phase classification • Trial completion • Essential Tremor • Movement Disorders

Modafinil and Cognitive Function in POTS (clinicaltrials.gov) - P1; N=20; Active, not recruiting; Sponsor: Vanderbilt University Medical Center; Trial completion date: Dec 2019 ➔ Dec 2020; Trial primary completion date: Dec 2019 ➔ Dec 2020

Trial completion date • Trial primary completion date